证券代码：688068 证券简称：热景生物 公告编号：2025-001 北京热景生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因回购期限内，公司股票价格持续超出回购股份方案中的回购价格上限，致 使公司可实施回购窗口较短，导致回购方案尚未实施。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出回 购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务，敬 请广大投资者注意投资风险。 特此公告。 一、 回购股份的基本情况 北京热景生物技术股份有限公司（以下简称"公司"）已于 2024 年 11 月 14 日召开第三届董事会第二十四次会议审议通过了《关于以集中竞价交易方式回购 公司股份方案的议案》，同意公司使用自有资金及自筹资金以集中竞价交易方式回 购公司已发行的部分人民币普通股（A 股）股票，为维护公司价值及股东权益。 公司本次回购价格不超过人民币 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-081 北京热景生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 三、 期限过半未实施回购原因 因回购期限内，公司股票价格持续超出回购股份方案中的回购价格上限，致 使公司可实施回购窗口较短，导致回购方案尚未实施。 四、 其他事项 一、 回购股份的基本情况 北京热景生物技术股份有限公司（以下简称"公司"）已于 2024 年 11 月 14 日召开第三届董事会第二十四次会议审议通过了《关于以集中竞价交易方式回购 公司股份方案的议案》，同意公司使用自有资金及自筹资金以集中竞价交易方式回 购公司已发行的部分人民币普通股（A 股）股票，为维护公司价值及股东权益。 公司本次回购价格不超过人民币 45 元/股（含），回购资金总额不低于人民币 5,800 万元（含），不超过人民币 10,000 万元（含），本次回购期限为自董事会审议 通过本次回购股份方案之日 3 个月内。 本事项具体内容详见公司分别于 2024 年 11 ...

Investment Rating - Buy rating for Rejing Biotech (688068) with first-time coverage [2] Core Views - Rejing Biotech is transitioning from specialty diagnostics to innovative drug development, aiming for a full industry chain strategy [5] - The company is expected to achieve revenues of 543/655/792 million yuan in 2024-2026, with net profits of 3/59/99 million yuan, and EPS of 0.04/0.64/1.07 yuan/share [5] - The current stock price corresponds to a PE ratio of 1759.7/97.8/58.7 times for 2024-2026 [5] IVD Business - Rejing Biotech has 19 years of experience in the IVD market, with leading diagnostic products in hepatitis, liver cancer, early cancer screening, and neurodegenerative diseases [5] - The company's single-use chemiluminescence products address pain points in grassroots testing, with rapid business growth [5] - The company has developed three major "National Health Projects" based on advanced glycocapture technology, focusing on liver, brain, and cancer health [5] - The company's chemiluminescence platforms, including MQ60 and C800/C900 series, cover a wide range of diagnostic needs [11] - The company has installed over 13,600 testing units of its single-use chemiluminescence immunoassay analyzers (MQ series) by June 30, 2024 [12] - The company's up-conversion luminescence technology platform is widely used in public safety, with products applied in major national events [14] Glycocapture Technology - Rejing Biotech has developed a comprehensive liver health management platform, covering the entire process from hepatitis to liver cancer diagnosis [15] - The company's "National Liver Health Project" includes diagnostic tools, early screening, and AI-based risk prediction models [15] - The global liver disease diagnosis market is expected to reach $21.29 billion by 2030, with a CAGR of 6.7% from 2024 to 2030 [17] - The company's CK18 chemiluminescence detection product, the first of its kind in China, has potential applications in fatty liver and weight loss clinics [19] - The company's glycocapture technology is also applied in cancer early screening, with products like GlyExo-Capture® and EXO-01 for exosome detection [22] - The company has established a "National Brain Health Project" focusing on Alzheimer's and Parkinson's diseases, with collaborations with leading research institutions [23] Innovative Drug Business - Rejing Biotech's subsidiary, Shunjing Pharmaceutical, has received IND approvals in both China and the US for its FIC product SGC001 (Dujipumab), a monoclonal antibody for acute myocardial infarction (AMI) [28] - SGC001 is the first-in-class drug for AMI, with potential to revolutionize emergency treatment for heart attacks [30] - The company has also established the "X-Gen AI Drug Discovery and Design Research Center" to accelerate new drug development [31] Financial and Equity Incentives - Rejing Biotech's revenue and net profit have been under pressure in 2023-2024 due to the high base effect from COVID-19 testing product sales [33] - The company's R&D expenses accounted for 20.0% of revenue as of June 30, 2024, with a cumulative investment of 77.2 million yuan [35] - The company has launched a new employee stock ownership plan, with a target revenue CAGR of 20% from 2024 to 2026 [39] Profit Forecast and Investment Recommendation - Rejing Biotech is expected to achieve significant growth in the coming years, driven by its innovative products in both IVD and drug development [42] - The company's revenue is projected to grow from 543 million yuan in 2024 to 792 million yuan in 2026, with net profits increasing from 3 million yuan to 99 million yuan [42]

证券代码：688068 证券简称：热景生物 公告编号：2024-080 北京热景生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/11/15 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 11 月 15 2 | | 日~2025 | 年 | 月 | 14 | 日 | | 预计回购金额 | 万元~10,000 万元 5,800 | | | | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | √为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 万股 | 0 | | | | | | | 累计已回购股数占总股本比例 | 0% | | | | | | | | 累计已回购金额 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-079 本次核心技术人员的调整不存在涉及职务发明专利权属纠纷或潜在纠纷 的情形，也不影响公司专利权属的完整性，亦不会对公司的核心竞争力、技术优 势、业务及产品创新能力产生实质影响。 公司本次新增认定的核心技术人员为公司现有研发骨干人才，有助于高 效推进公司研发项目，并为公司核心产品的技术升级及产业化提供有力支撑。 一、核心技术人员调整的具体情况 （一）调整核心技术人员的情况 根据公司战略发展规划，综合考虑公司研发项目战略布局，新认定陈建国为 公司核心技术人员，原核心技术人员黄鹤不再认定为核心技术人员，但仍继续在 子公司任职。 1、核心技术人员的具体情况 北京热景生物技术股份有限公司 关于调整核心技术人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京热景生物技术股份有限公司（以下简称"公司"）根据公司战略发展 规划，综合考虑公司研发项目战略布局以及原核心技术人员工作重心侧重和岗位 变化，公司对核心技术人员进行规划，新认定陈建国为公司 ...

Investment Rating - The report initiates coverage on Hotgen Biotech (688068 SH) with an "Overweight" rating [2] Core Views - Hotgen Biotech's IVD business is steadily growing, with its chemiluminescence business entering a rapid expansion phase The company's core business has maintained stable growth, with a CAGR of 18% for conventional business revenue from 2019 to 2023 [2] - The company has built eight technology platforms, including bio-active raw material R&D, sugar capture, magnetic particle chemiluminescence, up-conversion luminescence, colloidal gold immunochromatography, enzyme-linked immunosorbent assay, molecular diagnostics, and instrument R&D, continuously deepening its IVDT business [2] - The chemiluminescence platform has entered a rapid expansion phase, with revenue increasing by 45% in 2023 The company's employee stock ownership plan for 2024-2026 sets a revenue CAGR growth target of 20% or higher [2] Business Development - Hotgen Biotech has a strong R&D focus, with a 24 3% R&D expense ratio in 2023 Many core technical personnel come from military research institutes [3] - The company has established multi-omics diagnostic technology platforms, including protein marker sugar chain exosomes and DNA methylation, and has entered the drug R&D field through three subsidiaries: Yaojing Gene, Shunjing Pharma, and Yujing Pharma [3] - Shunjing Pharma's FIC product, SGC001, has entered dual reporting in China and the US SGC001 is a monoclonal antibody targeting S100A8/A9, indicated for acute myocardial infarction (AMI), and is the first FIC drug globally [3] Financial Projections - The company is expected to achieve revenues of 545/655/784 million yuan in 2024-2026, with net profits attributable to the parent company of 3/55/94 million yuan The corresponding PE valuations for 2024-2026 are 1444/74/43 times [4] - The company's non-COVID business is expected to grow steadily, and the innovation drug pipeline of its subsidiaries is progressing, supporting the "Overweight" rating [4] Industry and Market Analysis - Hotgen Biotech's products cover a wide range of clinical fields, including inflammation, infection, cardiovascular diseases, bone metabolism, thyroid function, diabetes, hypertension, hepatitis, liver cancer, tumors, kidney injury, and gastric function, widely used in hospitals, community health service stations, and third-party testing centers [50] - The company has a comprehensive product portfolio in the clinical reagent sector, with 13 approved cytokine detection reagents, maintaining a leading position in the cytokine detection field [54] - The company's public safety detection reagents cover biosecurity, foodborne pathogens, fungal toxins, and infectious diseases, widely used in disease control centers, public security, firefighting, military, and food safety monitoring [55] Innovation and R&D - Hotgen Biotech has established multiple advanced technology platforms, including phage display antibody preparation, sugar capture, magnetic particle chemiluminescence, and up-conversion luminescence, through years of development and collaboration with research institutions [69] - The company's GlyExo-Capture® technology, used for the extraction of glycosylated extracellular vesicles, has shown significant potential in early cancer diagnosis and screening, particularly in liver cancer [71] - The company continues to promote the "Chinese Liver Health Project," improving liver disease diagnosis and treatment levels through innovative products like the C-GALAD II liver cancer risk prediction model [77] Drug Development - Shunjing Pharma, a subsidiary of Hotgen Biotech, focuses on innovative drug R&D, with SGC001, a first-in-class drug for AMI, entering clinical trials in both China and the US [81] - SGC001 has shown promising preclinical data, significantly reducing mortality, myocardial infarction area, and improving heart function in animal models [90] - The drug has received IND approval from the US FDA and clinical trial approval from China's NMPA, with Phase II trials expected to begin in 2025 [92]

证券代码：688068 证券简称：热景生物 公告编号：2024-078 北京热景生物技术股份有限公司 关于公司及子公司近期获得资质情况的自愿披露 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 序号 产品名称 注册证号 类别 发证日期 有效期至 发证机构 1 25-羟基维生素 D 测定试 剂盒（磁微粒化学发光免 疫分析法） 京械注准 20242400630 II 2024/11/11 2029/11/10 北京市药品监督 管理局 2 细胞外囊泡分离提取仪 京兴械备 20240338 I 2024/11/14 长期 北京市大兴区市场 监督管理局 （二）获得境外认证情况 | | 疟疾 Pf/Pv 抗原检测 | Teste Rápido de | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 3 | | Antígeno PF/PV | 81285200018 | IV 类 | 2024/11/11 | 2034/11/11 | 巴西 | | | ...

Group 1 - The closing price of Hotgen Biotech (688068) on November 20 was 50.74 yuan, reaching the daily limit up with a trading volume of 7.14 billion yuan and a turnover rate of 16.44% [1] - The stock was listed on the trading board due to a price increase of 15% at the close [2] - The top five trading departments accounted for a total transaction of 2.39 billion yuan, with a net buying amount of 6.78 million yuan [2] Group 2 - The buying transaction amounted to 123 million yuan, while the selling transaction was 116 million yuan [2] - The stock experienced a price fluctuation of 20.24% throughout the trading day [1]

证券代码：688068 证券简称：热景生物 公告编号：2024-077 北京热景生物技术股份有限公司 关于回购股份事项前十名股东和前十名无限售条件 股东持股情况的公告 北京热景生物技术股份有限公司（以下简称"公司"）于 2024 年 11 月 14 日召开了第三届董事会第二十四次会议，审议通过了《关于以集中竞价交易方式 回购股份方案的公告》。具体内容详见公司于 2024 年 11 月 15 日在上海证券交 易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份方案的 公告》（公告编号：2024-073）。 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相 关规定，现将公司董事会公告回购股份决议的前一个交易日（即 2024 年 11 月 14 日）登记在册的前十名股东和前十名无限售条件股东的名称、持股数量和持 股比例情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | | 1 | 林长青 | 21,682,487 | 23.45 | | 2 | 周锌 | 6,806,629 | 7. ...

证券代码：688068 证券简称：热景生物 公告编号：2024-076 北京热景生物技术股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 相关股东是否存在减持计划：截至本公告披露日，公司控股股东、实际控制人、 董事、监事、高级管理人员、持股 5%以上股东在本回购方案实施期间暂不存在减 持公司股票的计划。未来若有股份减持计划，公司将严格遵守相关法律法规，履行 信息披露义务。 ● 相关风险提示： 1、本次回购股份存在回购期限内公司股票价格持续超出回购方案披露的价格 上限，导致回购方案无法顺利实施的风险； 2、若公司在实施回购股份期间，受外部环境变化、临时经营需要等因素影响， 致使本次回购股份所需资金未能筹措到位，可能存在回购方案无法实施或者部分 实施的风险； 3、若发生对公司股票交易价格产生重大影响的重大事项，或公司生产经营、 ● 回购股份金额：回购资金总额不低于人民币 5,800 万元（含），不超过人民币 10,000 万元（含）。 ● 回购股份资金 ...